ARID1A and colorectal cancer: Wei and colleagues described loss of ARID1A in colorectal cancer being associated with late TNM stage, poor pathological classification and distant metastasis, and concluded that patients with ARID1A-mutated cancers may benefit from therapy targeting chromatin modifying enzymes2.